FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research report issued to clients and investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($3.25) for the year, down from their previous forecast of ($3.24). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at ($1.62) EPS.

A number of other equities analysts also recently issued reports on IONS. Piper Sandler lowered their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Citigroup lowered their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. BMO Capital Markets lowered their price target on Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research report on Thursday, February 20th. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Two analysts have rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $60.00.

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock opened at $31.76 on Thursday. The company has a market capitalization of $5.05 billion, a P/E ratio of -10.45 and a beta of 0.34. The business’s 50 day moving average is $33.32 and its two-hundred day moving average is $37.98. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals has a 12-month low of $30.23 and a 12-month high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. Ionis Pharmaceuticals’s revenue for the quarter was down 30.2% compared to the same quarter last year. During the same period last year, the company earned $0.12 earnings per share.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in Ionis Pharmaceuticals during the fourth quarter worth $116,000. Woodline Partners LP acquired a new stake in Ionis Pharmaceuticals during the fourth quarter worth $3,762,000. Vestal Point Capital LP acquired a new stake in Ionis Pharmaceuticals during the fourth quarter worth $20,801,000. Two Sigma Advisers LP increased its stake in Ionis Pharmaceuticals by 1.3% during the fourth quarter. Two Sigma Advisers LP now owns 1,349,211 shares of the company’s stock worth $47,168,000 after acquiring an additional 16,800 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Ionis Pharmaceuticals by 0.3% in the fourth quarter. Two Sigma Investments LP now owns 921,439 shares of the company’s stock valued at $32,214,000 after buying an additional 2,362 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Insider Buying and Selling

In related news, CEO Brett P. Monia sold 33,445 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total transaction of $1,091,310.35. Following the transaction, the chief executive officer now owns 207,396 shares in the company, valued at approximately $6,767,331.48. This trade represents a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael R. Hayden acquired 5,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $36.22 per share, for a total transaction of $181,100.00. Following the transaction, the director now owns 35,219 shares of the company’s stock, valued at $1,275,632.18. This represents a 16.55 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 111,816 shares of company stock worth $3,603,914. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.